Vivos Therapeutics Reports Third Quarter 2021 Financial Results and Operational Update Third Quarter Revenue Increased Over 38% Year-Over-Year Expects to Benefit from Increased OSA Testing, Opening

Therapeutics Reports Third Quarter 2021 Financial Results

Quarter Revenue Increased Over 38% Year-Over-Year

Expects to Benefit from Increased OSA Testing,

Opening of Live Training Facility, Expansion

of Marketing Programs,

Additional FDA Approval and Positive Study

to Host Conference Call Today at 5:00 pm ET

RANCH, Colo., November 15, 2021 - Vivos Therapeutics, Inc. ("Vivos" or the "Company") (NASDAQ: VVOS),

a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering

from mild to moderate obstructive sleep apnea (OSA) and snoring in adults, today reported financial results and operating highlights

for the third quarter and nine months ended September 30, 2021.

and Operating Highlights:

"The third quarter saw many positive

developments for Vivos," said R. Kirk Huntsman, Vivos' Chairman and CEO. "We recorded strong year-over-year growth,

reflecting what we believe is growing recognition and adoption of our Vivos System as a treatment for mild to moderate sleep apnea. Our

sales growth during the quarter, most notably in appliances, is beginning to reflect the impact of our previously announced strategic

growth initiatives, including our expanded sales and marketing activities, featuring the broad introduction of our VivoScore diagnostic

program. While we experienced a late summer decline in new VIP enrollments due in part to COVID-19, we are now generating revenue outside

of our core of VIP enrollment revenue and appliance sales, including the value-added services we offer our VIPs and their patients as

well as the beginnings of management revenue from our Medical Integration Division."

continued, "Beyond our financial results, we celebrated a number of significant milestones in the quarter. Importantly, we received

510(k) market clearance for Vivos' mmRNA device for treating mild to moderate OSA, sleep-disordered breathing and snoring in adults.

This paves the way for expanded insurance reimbursement coverage as well as reimbursement from commercial payers. Also, we announced

the opening of The Vivos Institute international training center in Denver, Colorado. This 15,000 square-foot, state-of-the-art facility

bolsters our online training programs to offer advanced post-graduate education and training to dentists, dental teams and other healthcare

professionals from around the world in a live hands-on setting. We entered into a new cooperative relationship with Empower Sleep

to provide critical diagnostic and medical consultation services to people across North America who suffer from OSA. In more recent

weeks, we entered into a strategic collaboration with Candid Care. By combining our complementary strengths, together we will provide

an all-in-one, whole-mouth diagnosis and treatment solution for adult patients suffering from OSA."

"The third quarter also brought to light

the growing acceptance of our innovative diagnostic and treatment methods amongst members of the medical and dental communities. For

example, during the third quarter and year to date, we've seen significant growth and adoption of VivoScore diagnostic technology

for OSA, as measured by the number of sleep tests being performed. Between January and October of 2021, we saw a seven fold increase

in monthly diagnostic tests for OSA using VivoScore, with approximately 45% of patients testing positive. While we don't generate

revenue directly from VivoScore, the rapid rise in testing means that a core element of our marketing effort is gaining traction and

that more patients are becoming aware of their OSA condition and engaging in dialogue with their dentists and other healthcare providers

about treatment options, including the Vivos System. We are currently working very hard to help our VIP teams to convert those OSA positive

patients into Vivos System case starts. We continue to view VivoScore, not only as an important screening and diagnostic tool to promote

increased diagnoses of sleep apnea, but also as a key strategic marketing tool to generate greater usage of the Vivos System."

the quarter, we also began to expand the first phase of our go-to-market strategy of establishing a well-trained, independent Vivos provider

network across North America by taking our model to Dental Support Organizations (DSOs), which represent thousands of general dental

and specialty practices across North America. We are in active discussions with several DSOs representing several thousand dental practices

under management, and expect to launch pilot programs for the full implementation of the Vivos System and protocols within certain target

markets beginning in the fourth quarter of 2021 and early 2022."

"Simultaneously, we are actively expanding our social media marketing

outreach to engage more directly with consumers, medical providers and large employers. Going forward, we will continue to advance our

strategic growth actions to drive increased enrollment of new dentists as VIPs, as well as productivity growth and appliance sales among

existing VIPs, while working to foster greater brand recognition and broad acceptance among both providers and the general public. By

following this path, we are hopeful that many more OSA patients can be identified and ultimately receive the care they need to improve

their overall health and lead happier, fuller lives."

information on Vivos' financial results is included on the attached condensed consolidated balance sheets and statements of operations,

and additional explanations of Vivos' financial performance are provided in the Vivos' Quarterly Report on Form 10-Q

for the nine months ended September 30, 2021, which will be filed with the Securities and Exchange Commission ("SEC"). The

full 10-Q report will be available on the SEC Filings section of the Investor Relations section of Vivos' website at https://vivoslife.com/investor-relations/.

July, Vivos unveiled new data from an independent patient survey related to its proprietary Vivos treatment. The data showed nearly

97% of patients surveyed said that they had achieved their desired outcome from Vivos System treatment for their OSA.

in July, Vivos announced results from a national study commissioned by Vivos to assess patients' airway function and OSA symptoms

after undergoing the Vivos treatment. In the study, 28% of 74 adult patients treated with the Vivos' FDA Class 1 DNA appliance

for certain orofacial anomalies reported no remaining OSA symptoms, which is defined as patients having an Apnea Hypopnea Index (AHI)

score of less than five post-treatment. A more detailed summary of the national study results was released in August.

in July, Vivos announced the opening of The Vivos Institute training center in Denver, Colorado. The 15,000-square-foot facility

was established to provide advanced post-graduate education and training to dentists, dental teams and other healthcare providers from

around the world in a live and hands-on setting. The Institute's emphasis will be on educating healthcare providers about OSA and

Vivos' treatments for OSA within their practice areas, along with training on Vivos' related practice management tools for

August, Vivos announced the U.S. Food and Drug Administration (FDA) granted 510(k) market clearance to Vivos' mmRNA (modified mandibular

Repositioning Nighttime Appliance) device for treating mild to moderate OSA, sleep-disordered breathing and snoring in adults. This FDA

clearance paves the way for expanded insurance reimbursement coverage for the mmRNA device, including Medicare, as well as for potential

future government contracts and reimbursement from commercial payers that follow Medicare guidelines.

Also in August, Vivos announced a new

cooperative relationship with Empower Sleep, a San Bernadino, Calif.-based company empowering patients with affordable, accessible and

personalized telemedicine sleep care, to provide critical diagnostic and medical consultation services to people across North America

who suffer from OSA. Together, Vivos and Empower will provide a user-friendly platform with personalized insights for patients who are

being screened for OSA by North American dentists and other healthcare providers.

September, Vivos announced the formation of the Vivos Medical Consortium. This physician working group, Drs. Clete Kushida of Stanford

University and Cecilia Wu of the University of Alberta, will collaborate to advance Vivos' OSA technology capabilities and includes

renowned physicians with specialties in sleep medicine, neurology, pediatrics, pulmonology, anesthesiology, pain medicine, otolaryngology,

obstetrics and gynecology, cardiology, and forensic pathology from prominent academic institutions in the U.S. and Canada.

to quarter end, in October Vivos announced that results from a peer-reviewed, published study by Dr. Toshi Hart, DDS, Independent

Vivos Clinical Advisor, found a significant reduction of tooth decay in pediatric patients after undergoing treatment using Vivos'

FDA Class 1 registered Vivos Guide. The Vivos Guide is an oral appliance intended to address certain malocclusions

and developmental oral tissue anomalies, and has been found to help seal the lips to convert mouth breathing children to nose

breathing. Data from the study demonstrated that the risk reduction of tooth decay per child in the treatment group versus the control

group at six months and 12 months after beginning Vivos Guide use was lowered by 76.4% [p = 0.0004] and 57.9% [p = 0.05] respectfully.

Later in October, Vivos and Candid Care Co., a digital platform for oral

healthcare, today announced a new collaboration that will seek to provide patients with a comprehensive, whole-mouth solution to diagnose

and treat OSA in adult patients and provide orthodontic treatment from the same provider network. At the core of this collaboration, Vivos

and Candid will market each company's products and areas of expertise to deliver a comprehensive sleep and oral health solution

to patients in the United States and Canada. The focus of the collaboration will be Candid's CandidPro clear aligner for straightening

teeth and the Vivos System for treating OSA. The two companies will also share educational resources, training, and key opinion leaders

to bridge the gap between airway health and orthodontic therapy.

Vivos will conduct a conference call today,

November 15, 2021 at 5:00 p.m. (Eastern Time) to review the third quarter results as well as provide an overview of the Company's

recent milestones and growth strategy.

access the conference call, please dial (888) 394-8218, or for international callers, (720) 452-9217. A replay will be available shortly

after the call and can be accessed by dialing (844) 512-2921, or for international callers, (412) 317-6671. The passcode for the live

call and the replay is 5806322. The replay will be available until November 29, 2021.

live webcast of the conference call can be accessed on Vivos' website at https://vivoslife.com/investor-relations/. An online